...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chinese journal of digestive diseases >Prokinetic therapy for gastroenterological diseases
【24h】

Prokinetic therapy for gastroenterological diseases

机译：胃肠病的运动疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Normal propulsion of luminal contents through the gastrointestinal (GI) tract requires complex, coordinated neural and motor activity. Abnormalities can occur at a number of different levels, and there are numerous etiologies. everal drugs are proven to be effective in stimulating the motility of the GI tract. The most common medications used in the USA are erythromycin, metoclopramide, and neostigmine. A new prokinetic agent, tegaserod, has been recently approved, and other serotonin agonist agents are currently undergoing clinical studies. Cisapride has been withdrawn from the market because of its side-effects. Other prokinetics, such as domperidone, are not yet approved in the USA, although it is used in other countries. This review summarizes current knowledge of the mechanisms of GI motility disorders, as well as new agents that show promise as therapy.
机译：通过胃肠道（GI）正常推动内腔内容物需要复杂，协调的神经和运动活动。异常可以在许多不同的水平上发生，并且有许多病因。事实证明，普通药物均可有效刺激胃肠道的运动。在美国，最常用的药物是红霉素，甲氧氯普胺和新斯的明。最近批准了一种新的促运动剂替加色罗，而其他5-羟色胺激动剂也正在临床研究中。由于其副作用，西沙必利已退出市场。尽管其他国家使用了其他运动学，如多潘立酮，但尚未在美国获得批准。这篇综述总结了对胃肠动力障碍的最新知识，以及新的药物有望在治疗中发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号